Quantcast
Last updated on April 17, 2014 at 8:45 EDT

Latest Cephalon Inc. Stories

2014-03-07 20:22:28

COLUMBIA, S.C., March 7, 2014 /PRNewswire/ -- The South Carolina Court of Common Pleas, Fifth Judicial Circuit has issued a ruling that will allow the State of South Carolina to move forward with efforts to hold pharmaceutical giant, Cephalon, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., accountable for overpayments by the State Health Plan and for violations of the South Carolina Unfair Trade Practices Act. The court on February 21, denied Cephalon's motion for summary...

2014-02-04 08:34:45

DUBLIN, Feb. 4, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Bendamustine Hydrochloride for Injection, 25 mg/vial and 100 mg/vial. Actavis' ANDA product is a generic version of Cephalon's Treanda(®), a treatment for chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Cephalon, Inc. filed suit against Actavis on January 31,...

2013-07-31 12:27:23

MUMBAI and BALTIMORE, July 31, 2013 /PRNewswire/ -- elsPharma Major Lupin Limited announced today that its U.S. subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received tentative approval for its Armodafinil Tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths as well as another tentative approval for its Doxycycline Capsules, 40 mg (30 mg Immediate-release and 10 mg Delayed-release) from the United States Food and Drugs Administration (FDA). Lupin's...

2011-10-11 16:57:00

NEW YORK, Oct. 11, 2011 /PRNewswire/ -- TE Connectivity Ltd. (NYSE: TEL) will replace Cephalon Inc. (NASD: CEPH) in the S&P 500 index after the close of trading on Friday, October 14. Cephalon is being acquired by Teva Pharmaceutical Industries Ltd. (NASD: TEVA) in a deal expected to be completed on or about that date pending final approvals. S&P Indices will monitor this transaction, and post any relevant updates on its website: www.standardandpoors.com. TE Connectivity is a...

2011-08-22 07:34:00

FRAZER, Pa., Aug. 22, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) today provided notice to holders of its 2.50 percent Convertible Senior Subordinated Notes due 2014 (the "2014 Notes") and 2.00 percent Convertible Senior Subordinated Notes due 2015 (the "2015 Notes") in respect of the Merger (as defined below) of the Company with a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., an Israeli corporation ("Parent"), the consummation of which will constitute a Fundamental...

2011-08-02 15:10:00

FRAZER, Pa., Aug. 2, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported second quarter 2011 net sales of $730.1 million, a 2 percent increase compared to net sales of $712.4 million for the second quarter of 2010. Basic income per common share for the period was $1.54 compared to $1.18 for the second quarter of 2010. Excluding amortization expense and certain other items, adjusted net income for the second quarter of 2011 was $142.6 million, a 14 percent decrease versus...

2011-07-21 08:30:00

FRAZER, Pa., July 21, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA® (fentanyl buccal tablet) [C-II] and ACTIQ® (oral transmucosal fentanyl citrate) [C-II]. Both products are indicated for the management of breakthrough pain in opioid-tolerant patients with cancer. Under this REMS, pharmacies and healthcare...

2011-07-14 10:06:00

FRAZER, Pa., July 14, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that its stockholders voted to approve the Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) proposal to acquire Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion. The transaction remains under review by the U.S. Federal Trade Commission and the European Commission. Cephalon and Teva continue to operate as two independent companies pending those...

2011-07-14 07:00:00

Our 24/7 society means that some people have to work while the rest of us are sleeping, but at what cost to their health and well-being? WASHINGTON, July 14, 2011 /PRNewswire-USNewswire/ -- New survey results released today by Men's Health Network and Cephalon, Inc. found that shift workers, people who work non-traditional hours such as overnight shifts, report that these shifts can negatively impact their health, work and well-being. The survey revealed that the majority of shift...

2011-06-29 08:58:00

FRAZER, Pa., June 29, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) is scheduled to release its second quarter 2011 results via PRNewswire after the market close (approximately 4:10 p.m.) on Tuesday, August 2, 2011. Cephalon will not be holding a conference call to discuss these results. Cephalon Contacts:Media: Fritz BittenbenderO: 1 610 883 5855C: 1 610 457 7041fbittenb@cephalon.com Natalie de VaneO: 1 610 727 6536C: 1 610 999 8756ndevane@cephalon.com Investors: Cephalon...